与射频消融相比，微波消融治疗肝细胞癌的生存结果相似

StephenW

Microwave ablation determines similar survival outcomes as compared to radiofrequency ablation for the treatment of hepatocellular carcinoma
Amer Khan , Marcin Mostowy , Michael Owusu , Mercy Mutambanengwe , Sam Habimana , Somoskoi Bence & show all
Received 19 Nov 2020, Accepted 24 Dec 2020, Accepted author version posted online: 25 Dec 2020, Published online: 30 Dec 2020

    Download citation https://doi.org/10.1080/17474124.2021.1869939 CrossMark Logo CrossMark

ABSTRACT
Objectives

It is still unclear whether microwave ablation (MWA) outperforms radiofrequency ablation (RFA) in the treatment of hepatocellular carcinoma (HCC). Aim of this manuscript is to compare the two treatments through a meta-analysis of randomized-controlled trials (rcts).
Methods

Computerized bibliographic search was performed on main databases through August 2020. The primary outcome was the complete response rate, with survival rate, disease-free survival rate, and adverse event rate as secondary outcomes. Results were expressed in terms of risk ratio (RR) and 95% confidence interval (CI)
Results

Seven rcts enrolling 1143 patients were included. Rates of complete response were similar (RR 1.01, 95% CI 0.99–1.02); likewise, survival rates were constantly similar, with rrs ranging from 1.05 (0.96–1.15) at 1-year to 0.91 (0.81–1.03) at 5-year. Disease-free survival at 1-, 2-, and 3-year was similar between the two groups with RR 1.00 (0.96–1.04), 0.94 (0.84–1.06), and 1.06 (0.93–1.21), respectively. On the other hand, RR for disease-free survival at 5-year was significantly in favor of MWA (3.66, 1.32–42.27). Adverse event rate was similar between the two treatments (RR 1.06, 0.48–2.34), with bleeding and hematoma as most frequent complications.
Conclusions

MWA seems to determine similar outcomes as compared to RFA.

KEYWORDS: HCCrfamwasurvivalrecurrenceliver Cancer

StephenW

与射频消融相比，微波消融治疗肝细胞癌的生存结果相似
Amer Khan，Marcin Mostowy，Michael Owusu，Mercy Mutambanengwe，Sam Habimana，Somoskoi Bence和显示全部
于2020年11月19日接收，于2020年12月24日接受，在线接受作者版本：2020年12月25日，在线发布：2020年12月30日

    下载引文https://doi.org/10.1080/17474124.2021.1869939 CrossMark徽标CrossMark

抽象
目标

尚不清楚在肝细胞癌（HCC）的治疗中，微波消融（MWA）是否优于射频消融（RFA）。该手稿的目的是通过对随机对照试验（rcts）的荟萃分析来比较两种治疗方法。
方法

到2020年8月，对主要数据库进行了计算机书目搜索。主要结果是完整缓解率，生存率，无病生存率和不良事件发生率是次要结果。结果以风险比（RR）和95％置信区间（CI）表示
结果

纳入7例rct，共纳入1143例患者。完全缓解率相似（RR 1.01，95％CI 0.99–1.02）；同样，生存率一直相似，rrs从1年的1.05（0.96-1.15）到5年的0.91（0.81-1.03）不等。两组在1年，2年和3年的无病生存率相似，RR分别为1.00（0.96-1.04），0.94（0.84-1.06）和1.06（0.93-1.21）。另一方面，RR的5年无病生存率显着优于MWA（3.66，1.32–42.27）。两种疗法之间的不良事件发生率相似（RR 1.06，0.48–2.34），出血和血肿是最常见的并发症。
结论

与RFA相比，MWA似乎确定了相似的结果。

关键词：HCCrfamwasurvival复发肝癌